Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 liquidated — weigh against the wins.
1 vehicle on file, newest listing first
Debra Yu, M.D., has agreed to serve on our board of directors. Since October 2019, Dr. Yu serves as President and Chief Business Officer of LianBio, a company focused on developing therapeutic medicines in China. Prior to that, she was a Managing Director and the Head of Cross Border Healthcare Investment Banking at China Renaissance Securities (US) from August 2016 to September 2019 and has served as a Managing Director of Labrador Advisors from May 2009 to June 2016, where she advised numerous cross-border partnerships and licensing transactions. From January 2004 to June 2008, she was VP Strategy at WuxiApptec and helped to architect and co-lead Pfizer’s venture capital team and a member of Pfizer’s Worldwide Business Development organization. Dr.
This record is keyed to SEC CIK 0001869480 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 51 institutional-holder rows on these vehicles, under 24 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.